372 related articles for article (PubMed ID: 24406387)
1. Quantification of metamorphopsia in chronic central serous chorioretinopathy after half-dose verteporfin photodynamic therapy.
Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Mizota A; Yuzawa M
Retina; 2014 May; 34(5):964-70. PubMed ID: 24406387
[TBL] [Abstract][Full Text] [Related]
2. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Hashizume K; Mizota A; Yuzawa M
Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
[TBL] [Abstract][Full Text] [Related]
3. Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy.
Koytak A; Erol K; Coskun E; Asik N; Öztürk H; Özertürk Y
Retina; 2010; 30(10):1698-703. PubMed ID: 20539254
[TBL] [Abstract][Full Text] [Related]
4. Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results.
Fujita K; Yuzawa M; Mori R
Retina; 2011 Apr; 31(4):772-8. PubMed ID: 20890236
[TBL] [Abstract][Full Text] [Related]
5. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Cheng CK; Chang CK; Peng CH
Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
[TBL] [Abstract][Full Text] [Related]
6. Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial.
Wu ZH; Lai RY; Yip YW; Chan WM; Lam DS; Lai TY
Retina; 2011; 31(7):1378-86. PubMed ID: 21836413
[TBL] [Abstract][Full Text] [Related]
7. COMPARISON OF HALVING THE IRRADIATION TIME OR THE VERTEPORFIN DOSE IN PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Shiode Y; Morizane Y; Kimura S; Hosokawa M; Kawata T; Doi S; Hosogi M; Fujiwara A; Shiraga F
Retina; 2015 Dec; 35(12):2498-504. PubMed ID: 26035398
[TBL] [Abstract][Full Text] [Related]
8. Correlation of integrity of cone outer segment tips line with retinal sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
Fujita K; Shinoda K; Imamura Y; Matsumoto CS; Mizutani Y; Mizota A; Yuzawa M
Am J Ophthalmol; 2012 Sep; 154(3):579-85. PubMed ID: 22818904
[TBL] [Abstract][Full Text] [Related]
9. Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy.
Shinojima A; Kawamura A; Mori R; Fujita K; Yuzawa M
Retina; 2011 Oct; 31(9):1912-20. PubMed ID: 21952105
[TBL] [Abstract][Full Text] [Related]
10. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study.
Silva RM; Ruiz-Moreno JM; Gomez-Ulla F; Montero JA; Gregório T; Cachulo ML; Pires IA; Cunha-Vaz JG; Murta JN
Retina; 2013 Feb; 33(2):309-15. PubMed ID: 23095766
[TBL] [Abstract][Full Text] [Related]
11. Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
Gulkas S; Sahin O
Eur J Ophthalmol; 2020 Sep; 30(5):1053-1060. PubMed ID: 31256613
[TBL] [Abstract][Full Text] [Related]
12. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
[TBL] [Abstract][Full Text] [Related]
13. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ
Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
[TBL] [Abstract][Full Text] [Related]
14. A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.
Lai FH; Ng DS; Bakthavatsalam M; Chan VC; Young AL; Luk FO; Tsang CW; Brelén ME
Am J Ophthalmol; 2016 Oct; 170():91-99. PubMed ID: 27519561
[TBL] [Abstract][Full Text] [Related]
15. One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy.
Maruko I; Iida T; Sugano Y; Furuta M; Sekiryu T
Retina; 2011 Oct; 31(9):1921-7. PubMed ID: 21878850
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).
Lai TY; Wong RL; Chan WM
Trans Am Ophthalmol Soc; 2015; 113():T8. PubMed ID: 26755855
[TBL] [Abstract][Full Text] [Related]
17. Half-fluence photodynamic therapy in acute central serous chorioretinopathy.
Smretschnig E; Ansari-Shahrezaei S; Moussa S; Glittenberg C; Krebs I; Binder S
Retina; 2012; 32(10):2014-9. PubMed ID: 22466482
[TBL] [Abstract][Full Text] [Related]
18. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.
Nicolò M; Zoli D; Musolino M; Traverso CE
Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224
[TBL] [Abstract][Full Text] [Related]
19. Short-Term Retinal Sensitivity and Metamorphopsia Changes following Half-Fluence Photodynamic Therapy in Central Serous Chorioretinopathy.
Casalino G; Del Turco C; Corvi F; Rafaeli O; Bandello F; Querques G
Ophthalmic Res; 2016; 56(1):23-9. PubMed ID: 27003789
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy.
Tseng CC; Chen SN
Br J Ophthalmol; 2015 Aug; 99(8):1070-7. PubMed ID: 25680621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
